Recombinant human interleukin-10 inhibits proliferation of vascular smooth muscle cells stimulated by advanced glycation end products and neointima hyperplasia after carotid injury in the rat
- Author:
- No author available
- Journal Title:
- ACTA PHYSIOLOGICA SINICA
- Issue:
- 2
- DOI:
- 10.3321/j.issn:0371-0874.2003.02.003
- Key Word:
- 病理学;白介素10;肌;平滑;血管;晚期糖基化终产物;新生内膜增殖;pathology;interleukin-10;muscle;smooth;vascular;advanced glycation end products;neointima hyperplasia
Abstract： The purposes of this study was to determine the effects of recombinant human interleukin-10 (rhIL-10) on proliferation of vascular smooth muscle cells (VSMCs) stimulated by advanced glycation end products (AGE) and neointima hyperplasia after rat carotid arterial injury. Rat aortic VSMCs were cultured and treated with rhIL-10 or AGE respectively, and then co-treated with rhIL-10 and AGE. Proliferation of VSMCs was quantified by colormetric assay. Cell cycle analysis was performed by flow cytomertry. Sprague-Dawley rats were treated with recombinant human IL-10 (rhIL-10) for 3 d after carotid arteries injury. The ratio of neointima to media area at the site of arterial injury was measured 28 d after balloon injury. The p44/42 MAPK activity was evaluated by the immunoblotting technique using anti-p44/42 phospho-MAPK antibody. Compared to control, AGE stimulated VSMCs proliferation. rhIL-10 alone had no effect on VSMCs growth. With AGE stimulation, rhIL-10, at dose as low as 10 ng/ml, inhibited VSMCs growth (P<0.05). The cell number in G0/G1 phase of AGE and rhIL-10 co-treatment group was higher than that of AGE treatment alone (P<0.01) by flow cytometry analysis. Compared with the control group of neointima hyperplasia in rats, the ratio of neointima to media area of recombinant human IL-10 group was reduced by 45% (P<0.01). The p44/42 MAPK activity was significantly enhanced by AGE. The AGE effects were opposed by rhIL-10. The anti-inflammatory cytokine rhIL-10 inhibits AGE-induced VSMCs proliferation. Recombinant human IL-10 also inhibited neointima hyperplasia after carotid artery injury in rats. The results suggest the possibility that recombinant human IL-10, as a potential therapeutic approach, prevents neointimal hyperplasia.
- [1]Hiroaki Niiro,Takeshi Otsuka,Eiichi Ogami,etc.MAP Kinase Pathways as a Route for Regulatory Mechanisms of IL-10 and IL-4 Which Inhibit COX-2 Expression in Human Monocytes[J].1998,250(2).
- [2]Takahashi TA,Tadokoro K,Juji T,etc.Extracellular signal-regulated kinase, stress-activated protein kinase/c-Jun N-terminal kinase, and p38mapk are involved in IL-10-mediated selective repression of TNF-alpha-induced activation and maturation of human peripheral blood monocyte-derived[J].1999,162(7).
- [3]Kume S,Takeya M,Mori T,etc.Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody.[J].1995,147(3).
- [4]Teresa Krakauer.IL-10 inhibits the adhesion of leukocytic cells to IL-1-activated human endothelial cells[J].1995,45(1-2).
- [5]G L, King,M, Brownlee.The cellular and molecular mechanisms of diabetic complications.[J].1996,25(2).
- [6]Uyemura K,Demer L L,Castle S C,etc.Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis.[J].1996.
- [7]M. Ramani,V. Ollivier,F. Khechai,etc.Interleukin-10 inhibits endotoxin-induced tissue factor mRNA production by human monocytes[J].1993,334(1).
- [8]Rogers C.,Simon DI.,Edelman ER..A mAb to the beta(2)-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits[J].1998,95(17).
- [9]K W, Moore,R, de Waal Malefyt,R L, Coffman,etc.Interleukin-10 and the interleukin-10 receptor.[J].2001,19.
- [10]F Q, Cunha,S, Moncada,F Y, Liew.Interleukin-10 (IL-10) inhibits the induction of nitric oxide synthase by interferon-gamma in murine macrophages.[J].1992,182.
- [11]Z, Mallat,C, Heymes,J, Ohan,etc.Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death.[J].1999,19.
- [12]C, Rogers,F G, Welt,M J, Karnovsky,etc.Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin.[J].1996,16.
- [13]Farb A.,Sangiorgi G.,Carter A. J.,etc.Pathology of Acute and Chronic Coronary Stenting in Humans[J].1999.
- [14]Hiroaki Satoh,Masako Togo,Masumi Hara,etc.Advanced Glycation Endproducts Stimulate Mitogen-Activated Protein Kinase and Proliferation in Rabbit Vascular Smooth Muscle Cells[J].1997,239(1).
- [15]Ann Marie Schmidt,Shi Du Yan,Jean-Luc Wautier,etc.Activation of Receptor for Advanced Glycation End ProductsA Mechanism for Chronic Vascular Dysfunction in Diabetic Vasculopathy and Atherosclerosis[J].1999,84(5).
- [16]Leopold Oehler,Marietta Kollars,Barbara Bohle,etc.Interleukin-10 inhibits burst-forming unit-erythroid growth by suppression of endogenous granulocyte-macrophage colony-stimulating factor production from T cells[J].1999,27(2).
- [17]Jonasson L,Holm J,Skalli O,etc.Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis.[J].1985.
- [18]Kasper M,Funk RH.Age-related changes in cells and tissues due to advanced glycation end products (AGEs).[J].2001,32(3).
- [19]Poe JC,Miller RW,Stout RD,etc.CD40 signaling of monocyte inflammatory cytokine synthesis through an ERK1/2-dependent pathway. A target of interleukin (il)-4 and il-10 anti-inflammatory action.[J].1999,274(9).
- [20]Horiuchi S,Nagai R,Matsumoto K,etc.Receptors for proteins modified by advanced glycation endproducts (AGE)--their functional role in atherosclerosis.[J].1999,107(3).
- [21]A W, Clowes,M A, Reidy,M M, Clowes.Mechanisms of stenosis after arterial injury.[J].1983,49.
- [22]Yan SF,Yan SD,Schmidt AM,etc.The biology of the receptor for advanced glycation end products and its ligands.[J].2000,1498(2).
- [23]Michael Seitz,Pius Loetscher,Beatrice Dewald,etc.Interleukin-10 differentially regulates cytokine inhibitor and chemokine release from blood mononuclear cells and fibroblasts[J].1995,25(4).
- [24]Pober JS.Immunobiology of human vascular endothelium.[J].1999,19(2).
- [25]Tanaka H.,Sukhova G. K.,Swanson S. J.,etc.Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury[J].1993.
- [26]M, Kearney,A, Pieczek,L, Haley,etc.Histopathology of in-stent restenosis in patients with peripheral artery disease.[J].1997,95.